BusinessWire Feature Phase 1 Results for New Critical Priority Antibiotic from Helperby Therapeutics
- The combination is azidothymidine (AZT), a new class antibacterial, and low dose colistin.
- The combination is active against all three WHO Critical Priority Pathogens.
- AZT and colistin act synergistically against carbapenem and colistin-resistant Enterobacteriaceae (CRE) infections.
Helperby Therapeutics Ltd (Helperby) has presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Read The BusinessWire Article Announcing Helperby Results